Novavax Shares Face Mounting Survival Pressure

Novavax US6700024010

Novavax finds itself in a critical battle for corporate survival. The biotech firm’s stock is attempting to stabilize following a severe seven-day decline, caught between conflicting forces: a profitability timeline now pushed to 2028 and escalating demands from activist investors. The central question for market participants is whether Novavax can engineer a recovery or faces irreversible decline.

External pressure is intensifying as management pursues its long-term turnaround strategy. Major shareholder Shah Capital is aggressively pushing for the exploration of strategic alternatives, expressing clear dissatisfaction with the company’s commercial execution and what it terms the “slow adoption” of the protein-based vaccine.